OncoCyte launches kidney transplant test GraftAssure successfully

and launch a new test successfully. This is a significant step for OncoCyte. Josh Riggs highlighted that GraftAssure is designed to help manage kidney transplant patients by assessing the health of donated organs. The test is now available at several major transplant centers, which marks an important milestone for the company. During the call, Chief Financial Officer Andrea James provided financial updates. She reported that OncoCyte's revenues for Q4 2024 showed growth compared to the previous year. The financial results reflect the successful launch of new products and increased demand for their services. Riggs also discussed plans for the future. He mentioned that OncoCyte aims to expand its product offerings and continue developing innovative tests. The team is focused on bolstering their research to support better patient outcomes in the oncology and transplant fields. The executives expressed optimism about the company’s direction. They believe that with their ongoing efforts, OncoCyte can create a stronger impact in the healthcare sector. After the main presentations, analysts had the opportunity to ask questions about the company's strategies and upcoming plans.